The drugs are expensive, and experts say the recent spike in popularity has already led to shortages and increased hesitancy among insurance providers to cover these drugs
Providers on Klarity Health are independent practitioners with clinical autonomy
Their multifaceted mechanismsincluding weight loss, improved glycemic control, anti-inflammatory effects, and lipid profile enhancementcontribute to substantial cardiovascular benefits
Thus, GLP-1R-targeted nanotherapies for T2DM are primarily designed to enhance therapeutic convenience through oral or infrequent dosing and to improve efficacy through targeted pancreatic delivery, with the potential to substantially improve clinical outcomes
Obesity was present in 84%, and pre-existing diabetes was present in 23% of exposed pregnancies, reflecting a high-risk population
Our approach remains disciplined and value-focused, positioning this as a strong mid-to-long-term opportunity with meaningful upside. Srinivas Sadu, Executive Chairman, Gland Pharma | Q4 FY26 The neat thing about this bet is that these companies dont care who wins the Indian launch war
